Filing Flows › Standard Biotools (LAB) › Q1 2026
Standard Biotools (LAB) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Standard Biotools (LAB) reported revenue of $21.1M for the first quarter 2026 (Q1 2026), +5% from a year earlier and -11% from the quarter before. Operating margin was -59.1%, net earnings $127M (600.9% of revenue).
Standard Biotools, Q1 2026: revenue $21.1M (+5% year over year), operating margin -59.1%, net earnings $127M, operating cash flow −$46.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $21.1M | -11% | +5% |
| Operating profit | −$12.5M | — | — |
| Net earnings | $127M | +559% | — |
| Operating cash flow | −$46.6M | — | — |
What changed
Revenue was $21.1M in Q1 2026, up 5% year over year and down 11% from the previous quarter. Consumables was the largest line at 52% of revenue. Consumables added $2.8M year over year (up 35%), 308% of the total change. Instruments declined 33%.
Gross margin was 53.5%, down 1.2 points from Q1 2025. Operating costs exceeded revenue by $12.5M, an operating margin of -59.1%. Operating expenses fell 37% while revenue rose 5%. The fastest-growing cost line was Other operating costs (+12%). Net earnings were $127.1M. The effective tax rate was 0.0%. Non-operating items added $139.6M, 110% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$46.6M. Non-cash charges added back $1.4M of depreciation and amortization and $8.8M of share-based compensation. Working capital and other items used $183.9M. Capital expenditures of $570K exceeded it, leaving free cash flow of −$47.2M.
Questions
What was Standard Biotools' revenue in the first quarter 2026?
Standard Biotools (LAB) reported revenue of $21.1M for the first quarter 2026 (Q1 2026), +5% from a year earlier and -11% from the quarter before.
Was Standard Biotools profitable in the first quarter 2026?
Operating loss was $12.5M (-59.1% of revenue) and net earnings $127M.
Source: Standard Biotools 10-Q on SEC EDGAR.